Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Influenza A Virus, H5N1 Subtype”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Large-scale testing (Phase 3)Study completedNCT02107807
What this trial is testing

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Who this might be right for
Influenza, HumanFlu, HumanFlu, Avian+2 more
Seqirus 539
Testing effectiveness (Phase 2)Study completedNCT01910519
What this trial is testing

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Who this might be right for
Influenza A Virus, H5N1 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 50
Early research (Phase 1)Study completedNCT00408109
What this trial is testing

Safety Study of Avian Flu Vaccine

Who this might be right for
Influenza A Virus, H5N1 SubtypeInfluenza A VirusInfluenzavirus A+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 45
Early research (Phase 1)Study completedNCT00489931
What this trial is testing

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Who this might be right for
Influenza A Virus, H5N1 SubtypeInfluenza A VirusInfluenzavirus A+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 44
Early research (Phase 1)Study completedNCT02957656
What this trial is testing

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 53
Early research (Phase 1)Study completedNCT02274545
What this trial is testing

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 24
Early research (Phase 1)Study completedNCT02151344
What this trial is testing

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 100
Early research (Phase 1)Study completedNCT00755703
What this trial is testing

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Who this might be right for
Influenza A Subtype H5N1 Infection
Altimmune, Inc. 48
Not applicableStudy completedNCT01074736
What this trial is testing

Host Genetic Susceptibility to Avian Influenza A/H5N1

Who this might be right for
Influenza A Virus/H5N1 Subtype
South East Asia Infectious Disease Clinical Research Network 500
Not applicableNo Longer AvailableNCT03834376
What this trial is testing

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Who this might be right for
H7N9 Subtype of Influenza A Virus
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Looking for participantsNCT06842173
What this trial is testing

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Who this might be right for
Avian Influenza A Virus
Butantan Institute 700
Early research (Phase 1)Study completedNCT01086657
What this trial is testing

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Who this might be right for
Influenza A Virus, H5N1 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 64
Early research (Phase 1)Study completedNCT01675284
What this trial is testing

A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Who this might be right for
Bird FluAvian InfluenzaInfluenza A(H5N1)
Medigen Biotechnology Corporation 36
Testing effectiveness (Phase 2)Study completedNCT03497845
What this trial is testing

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Who this might be right for
Influenza A Virus, H5N1 Subtype
Biomedical Advanced Research and Development Authority 720
Early research (Phase 1)Study completedNCT02171819
What this trial is testing

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Who this might be right for
Influenza A Subtype H5N1 Infection
Institute of Vaccines and Medical Biologicals, Vietnam 75
Early research (Phase 1)Study completedNCT01657929
What this trial is testing

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Who this might be right for
Influenza A Subtype H5N1 Infection
Access to Advanced Health Institute (AAHI) 105
Early research (Phase 1)Study completedNCT01995695
What this trial is testing

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 48